10.1002/chem.201905651
Chemistry - A European Journal
RESEARCH ARTICLE
[21] Y. Wei, W. Fang, Z. Wan, K. Wang, Q. Yang, X. Cai, L. Shi, Z. Yang,
Virology Journal 2014, 11, 195.
[22] (a) P. Howarth, M. Emanuel, S. Holgate, Br. J. Pharmacol. 1984, 18, 1-
8. (b) D. M. Richards, R. N. Brogden, R. C. Heel, T. M. Speight, G. S.
Avery, Drugs 1984, 28, 38-61.
[23] M. P. Schön, M. Schön, British Journal of Dermatology 2007, 157, 8-13.
[24] A. W. Czarnik, US Patent App. 12/195,956 2009.
[25] G. Z. Feuerstein, J. Ruffolo, R. R., Eur. Heart J. 1995, 16, 38-42.
[26] (a) J. B. A. Thijssen, A. G. Knaeps, J. J. P. Heykants, J. Label Compd.
Radiopharm 1983, 20, 861-868. (b) S. G. Senderoff, A. J. Villani, S. W.
Landvatter, K. T. Games, J. R. Heys, J. Label Compd. Radiopharm 1993,
33, 1091-1105.
Christophe Dugave for their support in managing the ISOTOPICS
project. Further, we thank Dr. Volker Derdau and Dr. Jens Atzrodt
from Sanofi-Aventis Deutschland GmbH for valuable discussion
and supply with pharmaceuticals. PL thanks the CNRS for the
recurrent funding of fundamental research.
Keywords: Hydrogen Isotopic Exchange • Nanocatalysis • C-H
Activation • Deuterium • Tritium
[27] (a) G. Neugebauer, P. Neubert, Eur. J. Drug Metabo. Pharm. 1991, 16,
257-260. (b) P. M. Krstenansky, R. J. Cluxton, Drug Intell. Clin. Pharm.
1987, 21, 947-953.
[1]
[2]
E. Vitaku, D. T. Smith, J. T. Njardarson, J. Med. Chem. 2014, 57,
10257-10274.
K. Bourcier, R. Hyland, S. Kempshall, R. Jones, J. Maximilien, N. Irvine,
B. Jones, Drug Metabo. Dispos. 2010, 38, 923-929.
A. S. Bhatnagar, Breast Cancer Res. Treat. 2007, 105, 7-17.
D. J. Williamson, S. L. Shepheard, R. G. Hill, R. J. Hargreaves, Eur. J.
Pharmacol. 1997, 328, 61-64.
[3]
[4]
[5]
[6]
R. Kaur, A. R. Dwivedi, B. Kumar, V. Kumar, Anti-Cancer Agents Med.
Chem. 2016, 16, 465-489.
(a) R. Petrelli, P. Vita, I. Torquati, K. Felczak, D. J. Wilson, P. F. a. L.
Cappellacci, Recent Patents on Anti-Cancer Drug Discovery 2013, 8,
103-125. (b) G. C. Moraski, M. Chang, A. Villegas-Estrada, S. G.
Franzblau, U. Möllmann, M. J. Miller, Eur. J. Med. Chem. 2010, 45,
1703-1716. (c) S. Joshi, A. S. Bisht, D. Juyal, Pharma Innovation 2017,
6, 109.
[7]
(a) A. W. Schmidt, K. R. Reddy, H.-J. Knölker, Chem. Rev. 2012, 112,
3193-3328. (b) L. Yang, Y. Zhang, X. Zou, H. Lu, G. Li, Green Chem.
2018, 20, 1362-1366.
[8]
[9]
B. Wex, B. R. Kaafarani, J. Mater. Chem. C 2017, 5, 8622-8653.
(a) P. M. Laduron, P. F. Janssen, W. Gommeren, J. E. Leysen,
Molecular Pharmacology 1982, 21, 294-300. (b) P. J. S. Chiu, K. F.
Marcoe, S. E. Bounds, C.-H. Lin, J.-J. Feng, A. Lin, F.-C. Cheng, W. J.
Crumb, R. Mitchell, Journal of Pharmacological Sciences 2004, 95,
311-319.
[10] S. Wang, M. Cyronak, E. Yang, J. Pharm. Biomed. Anal. 2007, 43,
701-707.
[11] J. Atzrodt, V. Derdau, J. Label Compd. Radiopharm. 2010, 53, 674-
685.
[12] (a) J. Atzrodt, V. Derdau, W. J. Kerr, M. Reid, P. Rojahn, R. Weck,
Tetrahedron 2015, 71, 1924-1929. (b) A few other N-heterocyclic
scaffolds are known where HIE succeeded also on saturated
substituents through Ir(I) catalysis: W. J. Kerr, R. J. Mudd, M. Reid, J.
Atzrodt, V. Derdau, ACS Catal. 2018, 8, 10895-10900.
[13] R. Pony Yu, D. Hesk, N. Rivera, I. Pelczer, P. J. Chirik, Nature 2016,
529, 195 - 199.
[14] C. Zarate, H. Yang, M. t. J. Bezdek, D. Hesk, P. J. Chirik, J. Am. Chem.
Soc. 2019, 141, 5034-5044.
[15] (a) T. Pery, K. Pelzer, G. Buntkowsky, K. Philippot, H.-H. Limbach, B.
Chaudret, ChemPhysChem 2005, 6, 605-607; (b) I. Favier, S. P.
Massou, E. Teuma, K. Philippot, B. Chaudret, M. Gómez, Chem.
Commun. 2008, 3296-3298; (c) G. Pieters, C. Taglang, E. Bonnefille, T.
Gutmann, C. Puente, J.-C. Berthet, C. Dugave, B. Chaudret, B.
Rousseau, Angew. Chem. Int. Ed. 2014, 53, 230-234 ; (d) L. Gao, S.
Perato, S. Garcia-Argote, C. Taglang, L. M. Martínez-Prieto, C. Chollet,
D-A Buisson, V. Dauvois, P. Lesot, B. Chaudret, B. Rousseau, S.
Feuillastre, G. Pieters, Chem. Comm. 2018, 2986-2990 ; (e) A.
Palazzolo, S. Feuillastre, V. Pfeifer, S. Garcia-Argote, D. Bouzouita, S.
Tricard, C. Chollet, E. Marcon, D.-A. Buisson, S. Cholet, F. Fenaille, G.
Lippens, B. Chaudret, G. Pieters, Angew. Chem. Int. Ed. 2019, 58,
4891-4895.
[16] J. R. Heys, J. Label. Compd. Radiopharm. 2007, 50, 770-778.
[17] (a) C. Taglang, L. M. Martínez-Prieto, I. del Rosal, L. Maron, R. Poteau,
K. Philippot, B. Chaudret, S. Perato, A. Sam Lone, C. Puente, C. Dugave,
B. Rousseau, G. Pieters, Angew. Chem. Int. Ed. 2015, 54, 10474-10477.
(b) N. Rothermel, D. Bouzouita, T. Röther, I. del Rosal, S. Tricard, R.
Poteau, T. Gutmann, B. Chaudret, H.-H. Limbach, G. Buntkowsky,
ChemCatChem 2018, 10, 4243-4247.
[18] M. Yamamoto, K. Oshima, S. Matsubara, Heterocycles 2006, 67, 353-
359
[19] For the moment, no experimental evidence for rate acceleration of the H/D
exchange was found in the presence of a base using substrates that do
not contain acidic N-H bonds. Therefore, it is likely that the base facilitates
the N-H activation at the Ru nanocluster surface (for carbazole and indole
substructures) which led to the decrease of the activation barrier for the
C-H bond in β-position of the nitrogen atom.
[20] (a) J. Xiang, J. Wang, M. Wang, X. Meng, A. Wu, Tetrahedron 2014, 70,
7470-7475. (b) S. R. Naik, J. Harindran, A. B. Varde, J. Biotechnol. 2001,
88, 1-10.
This article is protected by copyright. All rights reserved.